Advertisement
Canada markets open in 4 hours 50 minutes

  • S&P/TSX

    21,823.22
    +94.67 (+0.44%)
     

  • S&P 500

    5,064.20
    +45.81 (+0.91%)
     

  • DOW

    38,225.66
    +322.37 (+0.85%)
     

  • CAD/USD

    0.7320
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    79.07
    +0.12 (+0.15%)
     

  • Bitcoin CAD

    81,171.26
    +2,109.02 (+2.67%)
     

  • CMC Crypto 200

    1,292.18
    +15.20 (+1.19%)
     

  • GOLD FUTURES

    2,308.30
    -1.30 (-0.06%)
     

  • RUSSELL 2000

    2,016.11
    +35.88 (+1.81%)
     

  • 10-Yr Bond

    4.5710
    -0.0240 (-0.52%)
     

  • NASDAQ futures

    17,753.75
    +104.00 (+0.59%)
     

  • VOLATILITY

    14.50
    -0.18 (-1.23%)
     

  • FTSE

    8,198.48
    +26.33 (+0.32%)
     

  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     

  • CAD/EUR

    0.6809
    -0.0008 (-0.12%)
     

After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study

Vandana Singh
·2 min read

Thursday, Candel Therapeutics Inc (NASDAQ:CADL) released updated interim survival data from the ongoing phase 2 trial of CAN-2409 plus valacyclovir (prodrug), together with standard of care (SoC) chemoradiation, followed by resection for borderline resectable pancreatic ductal adenocarcinoma.

Survival data were updated with eight months of further follow-up since the first analysis was presented at the 2023 Society for Immunotherapy Annual Meeting.

Also Read: Micro-Cap Cancer Focused Candel Therapeutics Highlights Encouraging Data From Brain Tumor Immunotherapy.

Data Highlights as of March 29, 2024, Data Cut-off, Include:

ADVERTISEMENT

Prolonged and sustained survival was observed after experimental treatment with CAN-2409 in patients with borderline resectable PDAC (n=13).

The estimated median overall survival was 28.8 months in the CAN-2409 group versus only 12.5 months in the control group.

At 24 months, a survival rate of 71.4% was observed in CAN-2409 treated patients after SoC chemoradiation and before surgery, versus only 16.7% in the control group.

At 36 months, a survival rate of 47.6% was estimated in patients who received CAN-2409, together with SoC chemoradiation before surgery, versus only 16.7% in the control group.

4 out of 7 patients who received CAN-2409 were still alive at the time of data cut-off, with two patients surviving more than 50.0 months from enrollment.

Only 1 out of 6 patients, randomized to control SoC chemotherapy, remained alive at data cut-off (alive at 50.6 months).

Previous analysis of blood and resected tumors showed consistent and robust activation of the immune response after experimental treatment with CAN-2409.

In pancreatic tissue of patients treated with CAN-2409 plus prodrug and SoC, dense aggregates of CD8+ granzyme B positive cytotoxic tumor-infiltrating lymphocytes, dendritic cells, and B cells were observed.

CAN-2409 continued to be associated with a favorable safety/tolerability profile.

The addition of the CAN-2409 regimen to SoC was generally well tolerated, with no dose-limiting toxicities, including no cases of pancreatitis.

Price Action: CADL shares are up 31.70% at $2.21 on the last check Thursday.

Photo via Shutterstock

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article After Brain Cancer Data, Candel Therapeutics' Shares Good News From Pancreatic Cancer Study originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.